One class of drugs in this category are histone deacetylase (HDAC) inhibitors, such as vorinostat (SAHA: suberoylanilide hydroxamic acid), the first clinical HDAC inhibitor approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma [3]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.